(The Hill) — President Trump's new pharmaceutical tariff policy throws another wrench into an already increasingly complex drug supply chain, with experts calling for more clarity and details on the White House's new policy set to go into effect in less than a week.

In announcing that branded or patented drugs would be hit with 100 percent tariffs on Oct. 1, Trump also said drugmakers could escape the penalties if they have a pharmaceutical manufacturing plant for which ground has been broken, or is currently under construction, in the U.S.

It’s unclear how many companies can escape the tariffs under that rule, though many drug manufacturers have pledged billions in investments into the U.S. under pressure from the Trump administration.

This announcement exempts generic drugs, which acc

See Full Page